Guard Therapeutics International AB
Clinical-stage biotech developing drugs to prevent acute kidney injury during open-heart surgery.
GUARD | ST
Overview
Corporate Details
- ISIN(s):
- SE0021181559
- LEI:
- 549300DTX7T87FGYG180
- Country:
- Sweden
- Address:
- Box 5216, 102 45 Stockholm
- Website:
- https://guardtherapeutics.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Guard Therapeutics International AB is a clinical-stage biotechnology company that identifies and develops novel therapies for diseases with significant unmet medical needs, with a primary focus on kidney disease. The company's main objective is the research, development, and eventual commercialization of drugs designed to protect against and treat acute kidney injury (AKI). Its lead drug candidate, RMC-035, is currently in Phase 2b clinical development for preventing AKI in patients undergoing open-heart surgery. The company's strategy is to advance its pipeline through clinical trials to offer new treatment options for kidney-related conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Guard Therapeutics International AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Guard Therapeutics International AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
